Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

"Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A serine/threonine protein kinase with GTPase activity that contains 12 LEUCINE-rich repeats in its central region and 7 WD repeats C-terminal to its kinase and GTPase domains. It localizes to TRANSPORT VESICLES; the OUTER MITOCHONDRIAL MEMBRANE; and the GOLGI APPARATUS. It functions in PROTEIN TRANSPORT; regulates neuron morphology in the central nervous system, and also functions in the trafficking of SYNAPTIC VESICLES. Mutations in the LRRK2 gene have been identified in autosomal dominant cases of PARKINSON DISEASE (PARK8).

Descriptor ID	D000071158
MeSH Number(s)	D08.811.913.696.620.682.700.534 D12.776.637.750
Concept/Terms	Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Leucine Rich Repeat Serine Threonine Protein Kinase 2 PARK8 Protein Dardarin Protein LRRK2 Protein

Below are MeSH descriptors whose meaning is more general than "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Serine-Threonine Kinases [D08.811.913.696.620.682.700]
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 [D08.811.913.696.620.682.700.534]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Parkinson Disease Associated Proteins [D12.776.637]
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 [D12.776.637.750]

Below are MeSH descriptors whose meaning is related to "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2".

Below are MeSH descriptors whose meaning is more specific than "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" by people in this website by year, and whether "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" was a major or minor topic of these publications.

Bar chart showing 7 publications over 5 distinct years, with a maximum of 3 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	0	1	1
2011	0	1	1
2014	0	1	1
2018	3	0	3
2020	0	1	1

Below are the most recent publications written about "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" by people in Profiles.

Schneider RB, Myers TL, Rowbotham HM, Luff MK, Amodeo K, Sharma S, Wilson R, Jensen-Roberts S, Auinger P, McDermott MP, Alcalay RN, Biglan K, Kinel D, Tanner C, Winter-Evans R, Augustine EF, Cannon P, Holloway RG, Dorsey ER. A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson's Disease: Study Protocol and Design. J Parkinsons Dis. 2020; 10(3):1195-1207.

View in: PubMed
Kishore A, Ashok Kumar Sreelatha A, Sturm M, von-Zweydorf F, Pihlstr?m L, Raimondi F, Russell R, Lichtner P, Banerjee M, Krishnan S, Rajan R, Puthenveedu DK, Chung SJ, Bauer P, Riess O, Gloeckner CJ, Kruger R, Gasser T, Sharma M. Understanding the role of genetic variability in LRRK2 in Indian population. Mov Disord. 2019 04; 34(4):496-505.

View in: PubMed
Kozina E, Sadasivan S, Jiao Y, Dou Y, Ma Z, Tan H, Kodali K, Shaw T, Peng J, Smeyne RJ. Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo. Brain. 2018 06 01; 141(6):1753-1769.

View in: PubMed
Xiong Y, Neifert S, Karuppagounder SS, Liu Q, Stankowski JN, Lee BD, Ko HS, Lee Y, Grima JC, Mao X, Jiang H, Kang SU, Swing DA, Iacovitti L, Tessarollo L, Dawson TM, Dawson VL. Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proc Natl Acad Sci U S A. 2018 02 13; 115(7):1635-1640.

View in: PubMed
Hockey LN, Kilpatrick BS, Eden ER, Lin-Moshier Y, Brailoiu GC, Brailoiu E, Futter CE, Schapira AH, Marchant JS, Patel S. Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition. J Cell Sci. 2015 Jan 15; 128(2):232-8.

View in: PubMed
Zhou H, Huang C, Tong J, Hong WC, Liu YJ, Xia XG. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int J Biol Sci. 2011; 7(6):753-61.

View in: PubMed
Han BS, Iacovitti L, Katano T, Hattori N, Seol W, Kim KS. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra. Neurosci Lett. 2008 Sep 19; 442(3):190-4.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement